Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Non-Deal Roadshow (March 2019)
24 slides from Telix Pharmaceuticals's roadshow presentation, Mar 26, 2019
Slide 1: Telix Pharmaceuticals Limited Non-Deal Roadshow March/April 2019
Telix Pharmaceuticals Limited ASX:TLX Non-Deal Roadshow March / April 2019
Slide 2: Notices
Notices The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implied, i
Slide 3: Company Snapshot
Melbourne Company Snapshot • Founded in 2015 by Dr. Chris Behrenbruch and Dr. Andreas Kluge, experienced nuclear medicine executives • Board : Kevin McCann (ex-Chairman, Macquarie Bank), Mark Nelson (Caledonia), Jann Skinner (ex-PwC Partner) and Oliver Buck (ITM Group) Kyoto • Melbourne (Australia)
Slide 4: Financial Snapshot
Financial Snapshot $0.67 (22nd of March,2019) Mkt. Cap: ~A$145m (~USD $100m) Disease Focus Oncology Clinical Stage Phase I - III Shares on Issue 218.4m Options on Issue 11.1m IPO Price: $0.65 Cash on Hand ~AUD $25m ASX Ticker TLX • Nov 2017 – $50m IPO on the Australian Securities Exchange (ASX). Rai
Slide 5: Our Approach: Molecularly-Targeted Radiation (MTR)
Our Approach : Molecularly-Targeted Radiation (MTR) MTR works by chemically “linking” radioactive isotopes to targeting molecules that are very specific for cancer cells. At low doses, this enables the location of the cancer cells to be pinpointed using PET imaging. At high doses the patient is very
Slide 6: See it, Treat it…
Positron Emission Tomography – “PET” See it, Treat it… • Telix develops drugs that deliver targeted radiation directly to cancer. At low radiation dose (or using diagnostic nuclides), the patient can be imaged The use of molecular imaging with PET enables a precision medicine approach to treatment t
Slide 7: Why is MTR so therapeutically effective?
Why is MTR so therapeutically effective? CONVENTIONAL TARGETED MOLECULARLY TARGETED RADIATION Non-Radioactive Drugs MTR Therapy 7
Slide 8: Clinical Pipeline
Clinical Pipeline Isotope Target Agent Phase I Phase II Phase III Commercial 177Lu CA-IX Antibody TLX250 (Girentuximab) Therapy Renal 89Zr CA-IX Antibody TLX250-Cdx (Girentuximab) Imaging Prostate 177Lu PSMA Antibody TLX591 TLX591 Therapy 68Ga Small Imaging PSMA TLX591-Cdx (PSMA-11) Molecule 131I Sm
Slide 9: Telix's Pipeline is a Multi-$Bn Opportunity
Telix’s Pipeline is a Multi-$Bn Opportunity* TLX101: The treatment of GBM is TLX591: Metastatic prostate cancer a $300m market opportunity with radionuclide therapy is $2Bn few beneficial options for patients opportunity in late-stage disease alone TLX250-CDx: Renal cancer patients are often mis-sta
Slide 10: TLX591-CDx (PCa Imaging)
▪ PSMA11 is the most widely used TLX591-CDx (PCa Imaging) PSMA prostate cancer agent ▪ In over 150 publications, PSMA11 68Ga-HBED- Prostate-Specific has demonstrated excellent Membrane detection of prostate cancer from CC-PSMA11 Antigen (PSMA) high-risk pre-prostatectomy patients to BCR and metastat
Slide 11: Early TLX591-CDx Adoption is Growing Fast
Early TLX591-CDx Adoption is Growing Fast 1 ✓ >100 sites around the world use the product routinely or 49 5 in clinical trials ✓ Mostly large cancer centres that are capable of doing 3 10-15 pts a week (upon 55 product approval) 8 2 8 1 1 ✓ Sales on track to deliver 7 3 between 10,000 and 1 15,000 d
Slide 12: TLX591 (PCa Therapy)
Retrospective cross-trial comparison between TLX591 (PCa Therapy) 177Lu-PSMA-617 and 177Lu-huJ591 (TLX591) Median overall survival (OS) is >40 months (hu591) vs 15 177Lu-DOTA- Prostate-Specific months Membrane huJ591 Antigen (PSMA) 6 Ph I/II trials Phase III >200 patients ▪ Antibody-based approach t
Slide 13: TLX250-CDx (Renal Ca Imaging)
TLX250-CDx (Renal Ca Imaging) Benign 89Zr-DFO- Carbonic Anhydrase IX girentuximab (CAIX) Malignant >300 patients imaged with Phase III ccRCC 124I, 89Zr (Confirmatory) ▪ Prior Ph III trial with 124I NCT03849118 ▪ ZIRDOSE 124I to 89Zr bridging ▪ 252 patient global phase III study, recruiting study com
Slide 14: TLX250 (Renal Ca Therapy)
TLX250 (Renal Ca Therapy) ▪ Average tumor increase (RECIST) in 177Lu-DOTA- Carbonic the 3 months prior to Anhydrase IX treatment was 40.4% girentuximab (CAIX) ▪ In the 3 months after 37 patients treatment it was 5.5% with 177Lu, Phase II ~900 for mAb ▪ >10 months PFS in heavily pre-treated STARLITE
Slide 15: TLX101 (Glioblastoma Therapy)
Image-based evaluations with MRI and PET are invaluable for measuring treatment TLX101 (Glioblastoma Therapy) response in GBM patients Case Study: LAT-1 131I-IPA • Treatment: 2GBq TLX101 single dose I.V. (Large Amino Acid Baseline F/U month 4 • Safety: no acute, sub-acute or delayed Transporter) tox
Slide 16: Multiple Milestones and Readouts in 2019
Multiple Milestones and Readouts in 2019 Q1 Q2 Q3 Q4 US/JP2 IND Filed Enrolment Complete Imaging Cancer Renal (Phase III) Therapy (Phase I/II) Mfg completed US IND Filed FPI Update Interim Results Info Package to FDA Pre-NDA meeting NDA Go/No Go Prostate Cancer Imaging NDA1 (US) TLX591 Therapy (Phas
Slide 17: Extensive Supply Chain and Production Network Established
Extensive Supply Chain and Production Network Established ✓ Key partners in place ✓ For clinical trials and early commercial product roll-out ✓ Discussion ongoing with partners for MENA, Asia and LATAM Backup 17
Slide 18: Competitive Landscape
Competitive Landscape ▪ Very few companies in the radiopharmaceutical / MTR space with a late-stage product pipeline. Telix is a unique company ▪ Moderate competition in prostate and GBM, zero meaningful competition in renal cancer ▪ Novartis (Endocyte / AAA) : have a Phase III prostate cancer progr
Slide 19: Valuation Benchmarks: Plenty of Sector Activity
Valuation Benchmarks : Plenty of Sector Activity ▪ Competing PhIII prostate ▪ Privately held UK program company, majority held ▪ Sold to Novartis in Dec by Syncona LIC. 2018 for USD $2.1Bn ▪ Est market cap of (AUD $2.9Bn) ~£200m (AUD $370m) ▪ Telix is successfully ▪ Limited pipeline, most of displac
Slide 20: Summary
Summary ✓ Excellent late-stage, de-risked clinical pipeline. Extensive patient data ✓ Pipeline delivers clear unmet medical need in high-value oncology segments – both diagnostically and therapeutically ✓ Experienced management team and board ✓ Extensive global supply chain and manufacturing footpri
Slide 21: www.telixpharma.com
www.telixpharma.com
Slide 22: Management Team
Dr. Michael Wheatcroft (Director of R&D) After completing a PhD in the Department of Biochemistry, Cambridge University, Mike Management Team worked at Cambridge Antibody Technology (now Medimmune). After moving to Melbourne in 2010, Mike oversaw the pre-clinical development of several engineered an
Slide 23: Board of Directors
Board of Directors Mr. H. Kevin McCann AM Ms. Jann Skinner Chairman Non-executive Director Kevin is currently Chairman of Citadel Group and former Chairman Ms. Skinner, B Com, FCA, FAICD has extensive experience in audit, accounting and in of Dixon Hospitality, Macquarie Bank Limited, Origin Energy,
Slide 24: International Scientific Advisory Board
International Scientific Advisory Board Dr. Rodney Hicks Dr. Neil Bander Chair of Urology at Weill Cornell Medical Centre (NY, USA). First led the Chief of Nuclear Medicine and Radiology, Peter MacCallum Cancer Centre development of PSMA-targeting radiopharmaceuticals for prostate (Melbourne, Austra
Telix Pharmaceuticals — Non-Deal Roadshow (March 2019) on 6ix